Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May;80(5-6):904–908. doi: 10.1038/sj.bjc.6690439

Somatic mutation of PTEN in bladder carcinoma

J S Aveyard 1, A Skilleter 1, T Habuchi 2, M A Knowles 1
PMCID: PMC2362287  PMID: 10360673

Abstract

The tumour suppressor gene PTEN/MMAC1, which is mutated or homozygously deleted in glioma, breast and prostate cancer, is mapped to a region of 10q which shows loss of heterozygosity (LOH) in bladder cancer. We screened 123 bladder tumours for LOH in the region of PTEN. In 53 informative muscle invasive tumours (≥ pT2), allele loss was detected in 13 (24.5%) and allelic imbalance in four tumours (overall frequency 32%). LOH was found in four of 60 (6.6%) informative, non-invasive tumours (pTa/pT1). We screened 63 muscle invasive tumours for PTEN mutations by single-strand conformation polymorphism (SSCP) analysis and for homozygous deletion by duplex quantitative polymerase chain reaction (PCR). Two homozygous deletions were identified but no mutations. Of 15 bladder tumour cell lines analysed, three showed homozygous deletion of all or part of the PTEN gene, but none had mutations detectable by SSCP analysis. Our results indicate that PTEN is involved in the development of some bladder tumours. The low frequency of mutation of the retained allele in tumours with 10q23 LOH suggests that there may be another predominant mechanism of inactivation of the second allele, for example small intragenic deletions, that hemizygosity may be sufficient for phenotypic effect, or that there is another target gene at 10q23. © 1999 Cancer Research Campaign

Keywords: PTEN, transitional cell carcinoma, bladder, chromosome 10, loss of heterozygosity

Full Text

The Full Text of this article is available as a PDF (120.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkin N. B., Baker M. C. Cytogenetic study of ten carcinomas of the bladder: involvement of chromosomes 1 and 11. Cancer Genet Cytogenet. 1985 Feb 15;15(3-4):253–268. doi: 10.1016/0165-4608(85)90169-4. [DOI] [PubMed] [Google Scholar]
  2. Babu V. R., Lutz M. D., Miles B. J., Farah R. N., Weiss L., Van Dyke D. L. Tumor behavior in transitional cell carcinoma of the bladder in relation to chromosomal markers and histopathology. Cancer Res. 1987 Dec 15;47(24 Pt 1):6800–6805. [PubMed] [Google Scholar]
  3. Berger C. S., Sandberg A. A., Todd I. A., Pennington R. D., Haddad F. S., Hecht B. K., Hecht F. Chromosomes in kidney, ureter, and bladder cancer. Cancer Genet Cytogenet. 1986 Sep;23(1):1–24. doi: 10.1016/0165-4608(86)90145-7. [DOI] [PubMed] [Google Scholar]
  4. Brewster S. F., Gingell J. C., Browne S., Brown K. W. Loss of heterozygosity on chromosome 18q is associated with muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer. 1994 Oct;70(4):697–700. doi: 10.1038/bjc.1994.376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cairns P., Evron E., Okami K., Halachmi N., Esteller M., Herman J. G., Bose S., Wang S. I., Parsons R., Sidransky D. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene. 1998 Jun 18;16(24):3215–3218. doi: 10.1038/sj.onc.1201855. [DOI] [PubMed] [Google Scholar]
  6. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J. G., Jen J., Isaacs W. B., Bova G. S., Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 1997 Nov 15;57(22):4997–5000. [PubMed] [Google Scholar]
  7. Cappellen D., Gil Diez de Medina S., Chopin D., Thiery J. P., Radvanyi F. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene. 1997 Jun 26;14(25):3059–3066. doi: 10.1038/sj.onc.1201154. [DOI] [PubMed] [Google Scholar]
  8. Chang W. Y., Cairns P., Schoenberg M. P., Polascik T. J., Sidransky D. Novel suppressor loci on chromosome 14q in primary bladder cancer. Cancer Res. 1995 Aug 1;55(15):3246–3249. [PubMed] [Google Scholar]
  9. Dahia P. L., FitzGerald M. G., Zhang X., Marsh D. J., Zheng Z., Pietsch T., von Deimling A., Haluska F. G., Haber D. A., Eng C. A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene. 1998 May 7;16(18):2403–2406. doi: 10.1038/sj.onc.1201762. [DOI] [PubMed] [Google Scholar]
  10. Dahia P. L., Marsh D. J., Zheng Z., Zedenius J., Komminoth P., Frisk T., Wallin G., Parsons R., Longy M., Larsson C. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997 Nov 1;57(21):4710–4713. [PubMed] [Google Scholar]
  11. Gibas Z., Prout G. R., Jr, Connolly J. G., Pontes J. E., Sandberg A. A. Nonrandom chromosomal changes in transitional cell carcinoma of the bladder. Cancer Res. 1984 Mar;44(3):1257–1264. [PubMed] [Google Scholar]
  12. Gray I. C., Phillips S. M., Lee S. J., Neoptolemos J. P., Weissenbach J., Spurr N. K. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res. 1995 Nov 1;55(21):4800–4803. [PubMed] [Google Scholar]
  13. Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A. F., Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 1997 Sep 1;57(17):3660–3663. [PubMed] [Google Scholar]
  14. Isshiki K., Elder D. E., Guerry D., Linnenbach A. J. Chromosome 10 allelic loss in malignant melanoma. Genes Chromosomes Cancer. 1993 Nov;8(3):178–184. doi: 10.1002/gcc.2870080307. [DOI] [PubMed] [Google Scholar]
  15. Jones M. H., Koi S., Fujimoto I., Hasumi K., Kato K., Nakamura Y. Allelotype of uterine cancer by analysis of RFLP and microsatellite polymorphisms: frequent loss of heterozygosity on chromosome arms 3p, 9q, 10q, and 17p. Genes Chromosomes Cancer. 1994 Feb;9(2):119–123. doi: 10.1002/gcc.2870090207. [DOI] [PubMed] [Google Scholar]
  16. Kagan J., Liu J., Stein J. D., Wagner S. S., Babkowski R., Grossman B. H., Katz R. L. Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. Oncogene. 1998 Feb 19;16(7):909–913. doi: 10.1038/sj.onc.1201606. [DOI] [PubMed] [Google Scholar]
  17. Kallioniemi A., Kallioniemi O. P., Citro G., Sauter G., DeVries S., Kerschmann R., Caroll P., Waldman F. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes Cancer. 1995 Mar;12(3):213–219. doi: 10.1002/gcc.2870120309. [DOI] [PubMed] [Google Scholar]
  18. Kallioniemi A., Kallioniemi O. P., Sudar D., Rutovitz D., Gray J. W., Waldman F., Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992 Oct 30;258(5083):818–821. doi: 10.1126/science.1359641. [DOI] [PubMed] [Google Scholar]
  19. Knowles M. A., Elder P. A., Williamson M., Cairns J. P., Shaw M. E., Law M. G. Allelotype of human bladder cancer. Cancer Res. 1994 Jan 15;54(2):531–538. [PubMed] [Google Scholar]
  20. Knowles M. A. Human papillomavirus sequences are not detectable by Southern blotting or general primer-mediated polymerase chain reaction in transitional cell tumours of the bladder. Urol Res. 1992;20(4):297–301. doi: 10.1007/BF00300263. [DOI] [PubMed] [Google Scholar]
  21. Knowles M. A., Williamson M. Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res. 1993 Jan 1;53(1):133–139. [PubMed] [Google Scholar]
  22. Kong D., Suzuki A., Zou T. T., Sakurada A., Kemp L. W., Wakatsuki S., Yokoyama T., Yamakawa H., Furukawa T., Sato M. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet. 1997 Oct;17(2):143–144. doi: 10.1038/ng1097-143. [DOI] [PubMed] [Google Scholar]
  23. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., Puc J., Miliaresis C., Rodgers L., McCombie R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997 Mar 28;275(5308):1943–1947. doi: 10.1126/science.275.5308.1943. [DOI] [PubMed] [Google Scholar]
  24. Liaw D., Marsh D. J., Li J., Dahia P. L., Wang S. I., Zheng Z., Bose S., Call K. M., Tsou H. C., Peacocke M. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997 May;16(1):64–67. doi: 10.1038/ng0597-64. [DOI] [PubMed] [Google Scholar]
  25. Marsh D. J., Dahia P. L., Zheng Z., Liaw D., Parsons R., Gorlin R. J., Eng C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet. 1997 Aug;16(4):333–334. doi: 10.1038/ng0897-333. [DOI] [PubMed] [Google Scholar]
  26. Nelen M. R., van Staveren W. C., Peeters E. A., Hassel M. B., Gorlin R. J., Hamm H., Lindboe C. F., Fryns J. P., Sijmons R. H., Woods D. G. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet. 1997 Aug;6(8):1383–1387. doi: 10.1093/hmg/6.8.1383. [DOI] [PubMed] [Google Scholar]
  27. Pesche S., Latil A., Muzeau F., Cussenot O., Fournier G., Longy M., Eng C., Lidereau R. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene. 1998 Jun 4;16(22):2879–2883. doi: 10.1038/sj.onc.1202081. [DOI] [PubMed] [Google Scholar]
  28. Polascik T. J., Cairns P., Chang W. Y., Schoenberg M. P., Sidransky D. Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. Cancer Res. 1995 Nov 15;55(22):5396–5399. [PubMed] [Google Scholar]
  29. Presti J. C., Jr, Reuter V. E., Galan T., Fair W. R., Cordon-Cardo C. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res. 1991 Oct 1;51(19):5405–5409. [PubMed] [Google Scholar]
  30. Proctor A. J., Coombs L. M., Cairns J. P., Knowles M. A. Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene. 1991 May;6(5):789–795. [PubMed] [Google Scholar]
  31. Rasheed B. K., Fuller G. N., Friedman A. H., Bigner D. D., Bigner S. H. Loss of heterozygosity for 10q loci in human gliomas. Genes Chromosomes Cancer. 1992 Jul;5(1):75–82. doi: 10.1002/gcc.2870050111. [DOI] [PubMed] [Google Scholar]
  32. Rempel S. A., Schwechheimer K., Davis R. L., Cavenee W. K., Rosenblum M. L. Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Cancer Res. 1993 May 15;53(10 Suppl):2386–2392. [PubMed] [Google Scholar]
  33. Rhei E., Kang L., Bogomolniy F., Federici M. G., Borgen P. I., Boyd J. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res. 1997 Sep 1;57(17):3657–3659. [PubMed] [Google Scholar]
  34. Risinger J. I., Hayes A. K., Berchuck A., Barrett J. C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997 Nov 1;57(21):4736–4738. [PubMed] [Google Scholar]
  35. Smeets W., Pauwels R., Laarakkers L., Debruyne F., Geraedts J. Chromosomal analysis of bladder cancer. III. Nonrandom alterations. Cancer Genet Cytogenet. 1987 Nov;29(1):29–41. doi: 10.1016/0165-4608(87)90028-8. [DOI] [PubMed] [Google Scholar]
  36. Steck P. A., Pershouse M. A., Jasser S. A., Yung W. K., Lin H., Ligon A. H., Langford L. A., Baumgard M. L., Hattier T., Davis T. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997 Apr;15(4):356–362. doi: 10.1038/ng0497-356. [DOI] [PubMed] [Google Scholar]
  37. Teng D. H., Hu R., Lin H., Davis T., Iliev D., Frye C., Swedlund B., Hansen K. L., Vinson V. L., Gumpper K. L. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 1997 Dec 1;57(23):5221–5225. [PubMed] [Google Scholar]
  38. Wang M. R., Perissel B., Taillandier J., Kémény J. L., Fonck Y., Lautier A., Benkhalifa M., Malet P. Nonrandom changes of chromosome 10 in bladder cancer. Detection by FISH to interphase nuclei. Cancer Genet Cytogenet. 1994 Mar;73(1):8–10. doi: 10.1016/0165-4608(94)90175-9. [DOI] [PubMed] [Google Scholar]
  39. Whang Y. E., Wu X., Suzuki H., Reiter R. E., Tran C., Vessella R. L., Said J. W., Isaacs W. B., Sawyers C. L. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246–5250. doi: 10.1073/pnas.95.9.5246. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES